AngelMD platform homepage. A community of physicians, dentists, startups, and industry insiders collaborating to accelerate health innovation — with access to 1,200+ emerging companies and nearly 2,000 investors.
A multi-sided healthcare investment platform connecting early-stage medical startups with a community of physician-investors. The core design challenge wasn't the UI — it was rearchitecting an account model that assumed users were one thing, when the reality of healthcare investing meant most were two or three at once.
When I joined AngelMD, the platform was built around a strict role-based model: you were either a physician, an investor, or a startup founder. Each role had its own onboarding path, its own interface assumptions, its own set of permissions and objectives. The design was clean and logical — if you accepted the premise that these three archetypes were mutually exclusive.
The premise was wrong. In healthcare investing, the most active and valuable users were physicians who were also investors. Some were founders building their own startups while advising others. The model that AngelMD had built didn't accommodate this reality — it forced users into a single lane and made the experience arduous for anyone whose professional identity crossed boundaries.
The fix wasn't cosmetic. It required rearchitecting the account model itself — moving from role-as-identity to role-as-layer. A single base account that a user could augment with clinical, investor, and founder profile layers, each activating the relevant features and objectives without forcing a choice that didn't reflect how users actually existed in the world.
The original architecture treated user type as a primary identity — a choice made at signup that determined everything downstream. Change your role, change your experience. The problem wasn't just UX friction — it was a structural ceiling on how engaged and valuable any individual user could become to the platform.
The new model introduced a Base Account as the universal foundation, with role-based profile layers that users could add over time. Each layer — Clinical, Investor, Founder — unlocked the relevant features and objectives for that context, while the base account maintained shared identity, network connections, and platform history across all of them.
The deal flow experience was the heart of what made AngelMD different from generic investment platforms. Deals didn't enter a single undifferentiated pool — they were surfaced and evaluated within specialty-specific physician groups (Advanced Surgery, Healthcare CEOs, Innovation4Alpha) where clinical expertise was embedded directly into the diligence process.
The pipeline tracked five stages — Referrals, Verified, Review, Diligence, Invest Ready — giving group members visibility into exactly where each opportunity stood and what action was needed from them. Action Items and Active Syndicates surfaced on the right rail, keeping members focused on decisions rather than discovery.
Syndicate investing — where a group of investors pools capital behind a single lead — is structurally complex and typically opaque. AngelMD's syndicate design made the group investment process transparent and social: visible progress toward funding targets, real-time investor counts, days remaining, and company information all surfaced on a single deal page.
The two states of a syndicate — Active and Round Closed — each carried different design priorities. Active deals needed urgency signals and clear calls to action. Closed rounds needed to communicate outcomes and preserve the record of the community's collective decision.
The mobile app brought the group-scoped feed and deal flow to a native experience. Context switching between groups — Advanced Surgery, Healthcare CEO, Innovation4Alpha — was built into the navigation header, giving users immediate access to the deals and community relevant to each of their professional contexts. The dark theme distinguished the app from the web platform and suited the high-focus investment context where users were reviewing deal materials on the go.
AngelMD was mismanaged at the leadership level — $2M burned on real estate annually while the product team shipped work that never reached users at scale. The pandemic hit in March 2020. By August, the company had stopped paying staff. I left to join DAT Freight & Analytics.
The design work was real. The account model rearchitecture was the right call and would have significantly improved activation and engagement if the company had survived long enough to ship it. The syndicate and deal flow system was genuinely differentiated for the space. The mobile app was polished and purposeful.
What the engagement taught me: design leadership isn't just about the quality of the work — it's about organizational health, financial stability, and whether leadership has the judgment to translate good design into business outcomes. The gap between exceptional design and shipped product is almost always a leadership problem, not a design problem.
In ten months — through organizational dysfunction, missed payroll, and a global pandemic — the design work produced a complete platform redesign across web and mobile, a rearchitected account model that solved a structural UX problem the original team had never identified, and a group investment experience that understood the social and clinical dynamics of physician-investor communities.